Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA Exploring the new frontiers of oncology Very serious about incurable diseases Breaking the impasse with novel therapeutic approaches Latest news Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs) January 5, 2023 Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development June 24, 2022 Diaccurate appoints Laurence Riot Lamotte as Chief Financial Officer February 8, 2022 See all press releases Upcoming events JP Morgan Healthcare Conference - Biotech Showcase | San Francisco January 9, 2023 - January 11, 2023 BIO Europe Spring | Basel, Switzerland March 20, 2023 - March 22, 2023 See all upcoming events
Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs) January 5, 2023
Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development June 24, 2022
JP Morgan Healthcare Conference - Biotech Showcase | San Francisco January 9, 2023 - January 11, 2023
